Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Biological significance of agmatine, an endogenous ligand at imidazoline binding sites

Open access
Raasch, Walter, Schäfer, Ulrich, Chun, Julian, Dominiak, Peter · 2001 · British Journal of Pharmacology

Abstract

Many publications have shown that imidazoline derivatives such as clonidine, moxonidine or rilmenidine reduce sympathetic tone via a central mechanism and that as a result they reduce plasma catecholamines and blood pressure (Reid et al., 1995). This reduction in blood pressure appears not to be regulated via peripheral, presynaptically localized receptors, since neither catecholamine depletion by reserpine, or destruction of the nerve endings with 6-hydroxydopamine produces a notable weakening of the clonidine-induced blood pressure reduction (Haeusler, 1974a,1974b; Kobinger & Pichler, 1976; Finch et al., 1975). In contrast, selective α2-adrenoceptor antagonists such as rauwolscine dose-dependently block hypotension induced by intravertebral application of clonidine. While some classical α2-adrenoceptor antagonists such as SKF86466 (in contrast to the imidazoline derivatives efaroxan and idazoxan) did not inhibit the clonidine-induced hypotension in the CNS (Ernsberger et al., 1988b; 1994; Haxhiu et al., 1994), this was discussed to due to underdosage of the antagonist (Bock et al., 1999). Hence the effects of clonidine are due to a central α2-adrenoceptor-mediated mechanism. The first signs that imidazoline derivatives might also work via non-adrenergic binding sites stem from Ruffolo (1977); the imadazoline derivative tetrahydrozoline was able to antagonize oxymetazoline-induced contraction, but not the contractile response induced by phenylethylamine derivatives such as noradrenaline, methoxamine or phenylephrine. Clear indications for a novel receptor type came from Bousquet et al. (1984), who reported hypotension after microinjection of clonidine into the rostroventrolateral medulla (RVLM). α-methylnoradrenaline showed no blood pressure reducing effect in the same model. The authors therefore assumed that binding sites must be present in the RVLM which preferentially bind imidazolines. Radioligand binding studies on RVLM membranes showed selective binding sites for imidazolines (Ernsberger et al., 1987). These data confirmed the assumptions of Ernsberger et al. (1988a; 1992); Buccafusco et al. (1995) and Bousquet et al. (1984) that the C1 region of the RVLM appeared to be the decisive area involved (Reis et al., 1989). Since then, two different imidazoline binding site subtypes have been identified (Michel & Insel, 1989; Michel & Ernsberger, 1992; Ernsberger et al., 1992). The I1-binding site, which shows a high affinity binding to [3H]-clonidine, is localized in the frontal cortex and the ventrolateral medulla (Bricca et al., 1989; Ernsberger et al., 1990a; 1992; Gomez et al., 1991), an area associated with central blood pressure regulation. Functionally, the I1-binding site seems to be involved in central blood pressure regulation (Ernsberger et al., 1988b; 1994; Haxhiu et al., 1994; Hamilton, 1992a,1992b; Hamilton et al., 1992; Hieble & Ruffolo, 1992), even though its importance remains largely unclarified, since in functional α2A-adrenoceptor 'knock out' mice (D79N; Macmillan et al., 1996) no evidence of I1-imidazoline binding site-mediated effects was revealed (Zhu et al., 1999). Its amino acid sequence and the DNA coding for it also remain to be determined, although an imidazoline binding site antisera cDNA has been isolated and characterized as encoding a 1504 amino acid protein (IRAS-1) showing properties of an I1-binding site (Piletz et al., 2000). I1-binding sites have also been demonstrated in the spinal cord, kidney and pancreas (Regunathan et al., 1993; Ernsberger et al., 1995; Schulz & Hasselblatt, 1989a), but not in the left ventricle (Raasch et al., 2000). Unlike the I1-binding site, the role of the I2-binding sites has been better characterized, whereby I2-binding sites can be further differentiated amongst I2A- and I2B-binding sites depending on their amiloride sensitivity. I2 binding sites have been demonstrated in various tissues such as brain (Brown et al., 1990), liver (Tesson & Parini, 1991) and kidney (Michel et al., 1989), whereby studies by Tesson et al. (1991) concluded that they are associated with mitochondria. Further studies focused their localization to the outer mitochondrial membrane. Functionally, the I2-binding site has been characterized as a regulatory subunit of monoamine oxidase (MAO, Figure 1), and later on it became clear that both MAO A and B share the same I2-binding site as a novel domain on the protein (Limon et al., 1992; Olmos et al., 1993). Moreover, studies on MAO A- and MAO B-deficient mice indicate that (1) the I2 binding sites identified by [3H]-idazoxan reside solely on MAO B, and (2) the binding sites on MAO A and a 28-kDa protein identified in livers of MAO A- and MAO B-deficient mice by photolabelling with 2-[3-azido-4-[(125)l]iodophenoxyl]methylimidazoline ([125I]-AZIPI) may represent additional subtypes of the imidazoline-binding site family (Remaury et al., 2000). In vitro studies have shown that selective ligands of the I2-binding site reduc

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0704153

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 183

Metadata

Authors
Raasch, W., Schäfer, U., Chun, J., & Dominiak, P.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2001-07
Volume
133
Issue
6
Pages
755-780
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2028492108
Cited by
183
References
2
FWCI
3.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. https://app.cochat.ai/papers/10.1038/sj.bjp.0704153
The paper
Raasch, W., Schäfer, U., Chun, J., & Dominiak, P. (2001). Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0704153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.